18,451 reports of this reaction
2.4% of all DUPILUMAB reports
#10 most reported adverse reaction
CONDITION AGGRAVATED is the #10 most commonly reported adverse reaction for DUPILUMAB, manufactured by sanofi-aventis U.S. LLC. There are 18,451 FDA adverse event reports linking DUPILUMAB to CONDITION AGGRAVATED. This represents approximately 2.4% of all 782,562 adverse event reports for this drug.
Patients taking DUPILUMAB who experience condition aggravated should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONDITION AGGRAVATED is a less commonly reported adverse event for DUPILUMAB, but still significant enough to appear in the safety profile.
In addition to condition aggravated, the following adverse reactions have been reported for DUPILUMAB:
The following drugs have also been linked to condition aggravated in FDA adverse event reports:
CONDITION AGGRAVATED has been reported as an adverse event in 18,451 FDA reports for DUPILUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONDITION AGGRAVATED accounts for approximately 2.4% of all adverse event reports for DUPILUMAB, making it a notable side effect.
If you experience condition aggravated while taking DUPILUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.